Skip to main content
. Author manuscript; available in PMC: 2016 Sep 27.
Published in final edited form as: Acta Neuropathol. 2016 Feb 26;131(6):847–863. doi: 10.1007/s00401-016-1549-x

Table 2.

FGFR1 positive cases in the study and their detailed mutational status and phospho-ERK IHC results

Case Diagnosis Location Age Sex Tumor Mutation Phospho-ERK IHC

3 DNET Midline (septum pellucidum) 27 male Primary tumor FGFR1 full gene duplication Nuclear
4 DNET R, Temporo-frontal 21 male Primary tumor p.K656D Nuclear & cytoplasmic
5 DNET R, Temporal 38 female Primary tumor TKD Nuclear
6 DNET R, Temporo-mesial 42 male Primary tumor p.K656E Nuclear
7 DNET R, Temporo-parietal 26 male Primary tumor p.N546K Nuclear (<5% cytoplasmic)
8 DNET R, Temporo-mesial 43 female Recurrence TKD Nuclear & cytoplasmic
9 DNET R, Parietal 18 male Primary tumor p.K656E+p.K655V Nuclear
10 DNET R, Parietal 12 male Primary tumor p.K656E+p.E633A+p.D652G+p.A640A Nuclear & cytoplasmic
11 DNET R, Parietal 12 male Recurrence of case 10 p.K656E+p.E633A+p.D652G+p.A640A Nuclear
14 DNET L, Temporal 8 male Primary tumor TKD Nuclear & cytoplasmic
15 DNET R, Occipital 14 male Primary tumor TKD Nuclear & cytoplasmic
16 DNET L, Frontal 30 male Primary tumor p.K656D Nuclear & cytoplasmic
18 DNET R, Frontal 6 male Primary tumor TKD Nuclear & cytoplasmic
19 DNET R, Frontal 18 female Recurrence FGFR1-TACC1 fusion Nuclear
20 DNET L, Temporal 1mo female Primary tumor FGFR1 breakpoint Nuclear
23 DNET L, Temporal 13 male Primary tumor FGFR1 breakpoint Nuclear
26 DNET-like R, Temporal 31 male Primary tumor p.K656E Nuclear & cytoplasmic
32 DNET L, Temporo-mesial 12 female Primary tumor p.K656E+ p.K655I Nuclear & cytoplasmic
33 DNET L, Temporo-mesial 17 female Recurrence of case 32 p.K656E+ p.K655I Nuclear & cytoplasmic
36 DNET L, Temporo-mesial 5 male Primary tumor p.K656D Nuclear
38 DNET R, Temporal 13 male Recurrence p.N546K Nuclear & cytoplasmic
40 DNET-like N/A 38 female Primary tumor p.N546K + FGFR1 breakpoint N/A, high background
42 DNET-like~ L, Frontal opperculum 20 female Primary tumor p.K656E+ p.D652G N/A, high background
45 DNET-like L, Frontal 3mo female Recurrence TKD Nuclear & cytoplasmic
50 DNET R, Occipital 1 female Primary tumor TKD Nuclear & cytoplasmic
51 DNET L, Frontal 4mo female Primary tumor TKD Nuclear & cytoplasmic
52 DNET R, Temporal 6mo female Primary tumor TKD Nuclear & cytoplasmic
59 DNET R, Parieto-occipital 1mo male Primary tumor TKD Nuclear & cytoplasmic
60 DNET R, Parieto-occipital 14 male Recurrence of 59 TKD Nuclear & cytoplasmic
61 DNET L, Frontal 1mo female Primary tumor TKD Nuclear & cytoplasmic
62 DNET R, Temporo-parietal 1mo female Primary tumor TKD Nuclear & cytoplasmic
66 DNET R, Parieto-occipital 1mo male Primary tumor p.K656D Nuclear & cytoplasmic
68 DNET-like Temporal 17 male Primary tumor p.K656D Nuclear & cytoplasmic
87 DNET-like Temporal 31 female Primary tumor p.K656E Nuclear & cytoplasmic
97 DNET-like Temporal 30 male Primary tumor p.N546K Nuclear & cytoplasmic
98 DNET-like^ L, Medial temporal 13 female Primary tumor p.N546K Nuclear
100 DNET-like Posterior insula, L temporal lobe 4 female Recurrence p.N546K+ p.K656N Nuclear & cytoplasmic

TKD = tyrosine kinase domain

NB: p.K656D can only be achieved by a double mutation c.1966A>G +c.1968G>C.

Aberrant phospho-ERK IHC expression was considered when the protein was expressed both in nucleous and cytoplasm.

~

due to low tumor, a final diagnosis was not achieved. So, to be conservative, it was grouped amongst the DNET-like

^

sample was considered as a possible DNET but, to be conservative, was grouped amongst the DNET-like